Publicly insured Americans who undergo lung transplantation for cystic fibrosis fare markedly worse in the long run than both publicly insured patients in the United Kingdom and privately insured Americans, according to the results of a study conducted by researchers from Johns Hopkins in Baltimore and UK colleagues working in that nation’s government-funded National Health Service.

The analysis, based on a review of medical records and published March 24 in the American Journal of Transplantation, reveals that publicly insured USĀ patients had overall poorer survival compared with their U.K. counterparts insured by the National Health Service. U.S. patients on Medicaid or Medicare insurance also fared worse than their privately insured fellow Americans.